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Abstract
Background and Aims: Inflammation has long been regarded as a major contributor to cellular 
oxidative damage and to be involved in the promotion of carcinogenesis.
Methods: We aimed to investigate the oxidative damage in inflammatory bowel disease [IBD] 
patients through a case–control and prospective study involving 344 IBD patients and 294 healthy 
controls. DNA damage and oxidative DNA damage were measured by comet assay techniques, 
and oxidative stress by plasmatic lipid peroxidation, protein carbonyls, and total antioxidant 
capacity.
Results: Higher DNA damage [p < 0.001] was found both in Crohn’s disease [CD] (9.7 arbitrary 
units [AU]; interquartile range [IQR]: 6.2–14.0) and ulcerative colitis [UC] [7.1 AU; IQR: 4.4–11.7], 
when compared with controls [5.4 AU; IQR: 3.8–6.8], and this was also the case with oxidative 
DNA damage [p < 0.001] [CD: 3.6 AU; IQR: 1.8–6.8; UC: 4.6 AU; IQR: 2.4–8.1], when compared with 
controls: 2.3 AU; IQR: 1.2–4.2]. Stratifying patients into groups according to therapy (5-aminosalicylic 
acid [5-ASA], azathioprine, anti-TNF, and combined therapy [azathioprine and anti-TNF]) revealed 
significant between-group differences in the level of DNA damage, both in CD and UC, with the 
combined therapy exhibiting the highest DNA damage levels [11.6 AU; IQR: 9.5–14.3, and 12.4 
AU; IQR: 10.6–15.0, respectively]. Among CD patients, disease behaviour [B1 and B2], and age at 
diagnosis over 40 years [A3] stand as risk factors for DNA damage. For UC patients, the risk factors 
found for DNA damage were disease activity, treatment, age at diagnosis under 40 years [A1 + A2] 
and disease locations [E2 and E3].
Conclusions: In IBD there is an increase in DNA damage, and treatment, age at diagnosis and 
inflammatory burden seem to be risk factors.
Key Words:  Inflammatory bowel disease; DNA damage; risk factors
Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/10/11/1316/2479998
by guest
on 06 August 2018
DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease 1317
1. Introduction
Inflammatory bowel diseases [IBDs] (both Crohn’s disease [CD] and 
ulcerative colitis [UC]) are relapsing inflammatory conditions with 
still-growing prevalence worldwide.1 Genetic, immunological and 
environmental factors are involved in IBD.2 The chronic inflamma-
tion along the gastrointestinal tract that characterizes IBD results 
from an imbalance of effector lymphocytes and pro-inflammatory 
cytokines with respect to regulatory lymphocytes and cytokines.3 
Some of the cytokines, as well as the triggered leukocytes and acti-
vated macrophages, can produce large amounts of reactive oxygen 
species [ROS], thus predisposing a patient to oxidative stress dis-
turbances.4 It has been shown that exposure to activated leukocytes 
can cause DNA base modifications in human cells, and the oxida-
tive DNA damage is closely related to a lifelong increased risk of 
cancer development.5 The activation of inflammation can result in 
genetic and epigenetic transformations that may promote carcino-
genesis,6 and the increase of mortality and morbidity in IBD is due 
to increased incidence of colorectal cancer [CRC].7 Conventional 
treatments in IBD such as anti-inflammatory drugs [sulfasalazine, 
mesalazine], corticosteroids [prednisolone, methylprednisolone, 
budesonide], antibiotics, and immunosuppressants [azathioprine, 
6-mercaptopurine] are known to have direct anti-oxidative effects 
via free radical scavenging properties8; on the other hand, biologic 
therapies (anti-tumour necrosis factor-alpha [TNF-α] monoclonal 
antibodies), used in the treatment of moderate–severe disease or 
in cases of refractoriness, have an indirect anti-oxidative effect by 
decreasing the TNF-α concentrations.8
To assess whether IBD may impose oxidatively damaged DNA, 
we decided to measure peripheral DNA damage [through the alka-
line comet assay] and oxidative DNA damage (through the forma-
midopyrimidine glycosylase [FPG] enzyme version of the comet 
assay) in isolated lymphocytes, as these are often used as surrogate 
cells to estimate oxidative stress affecting other tissues. Plasma lipid 
peroxidation, protein carbonylation content, and total antioxidant 
capacity were also measured, and clinical data were gathered from 
patients, in order to determine which factors are more pertinent in 
contributing to the oxidative burden in IBD, and which may be pre-
dictive for DNA damage.
2. Materials and Methods
2.1. Study population
A total of 638 subjects were enrolled in this study. Patients were 
recruited from the Gastroenterology Unit of Hospital S.  João, 
Porto, Portugal, as they attended their routine IBD specialist medi-
cal appointment. All patients were observed by the same physician 
for several years, which turns the clinical decisions more homoge-
neous. Of the 638 patients, 344 [221 with CD and 123 with UC] 
were eligible, and their samples were collected throughout the year 
of 2012. The control group consisted of healthy blood donors who 
attend the Blood Bank Unit of Centro Hospitalar S. João, and 294 
sex- and age-matched samples were collected. The Ethics Committee 
of Hospital S. João approved the protocol, and all patients or their 
legal guardians gave their written informed consent, complying with 
the principles laid down in the Declaration of Helsinki. A question-
naire concerning each patient’s disease characteristics was filled out 
by the physician, and all data was prospectively compiled in a data-
base [gediibasedados.med.up.pt]. Information on smoking habits, 
disease score, extra-intestinal manifestations, location and behav-
iour of disease, therapeutic in use, duration of disease, number of 
flares, and duration of current therapy was collected. Patients were 
considered eligible based on their current therapy: 5-aminosali-
cylic acid [5-ASA], azathioprine, anti-TNFα, and combined therapy 
of azathioprine and anti-TNFα users were included in the study. 
Location, behaviour, and age at diagnosis, were classified according 
to the Montreal Classification.9 C-reactive protein [C-RP] determi-
nation was also requested on sample collection.
2.2. Samples
Two blood samples were collected from each subject into heparin-
ized tubes [BD Vacutainer, USA]. Peripheral blood mononuclear cells 
[PBMCs] were separated from whole blood, by Histopaque-1077™ 
[Sigma-Aldrich, USA] density gradient centrifugation following the 
manufacturer’s instructions and slowly frozen to –80ºC and kept 
until analysis. Lymphocyte viability was measured by Trypan blue 
dye exclusion assay. All processed samples were found eligible for 
comet assay [viability > 90%].10
2.3. Comet assay for DNA damage and  
FPG-sensitive sites determination
The medium-throughput alkaline version11 of comet assay was per-
formed as described previously.12 Before proceeding to the scor-
ing step, slides were dyed SYBRGold™ [Invitrogen, Massachusetts, 
USA] at the dilution recommended by the manufacturer for 15 min. 
Oxidative DNA damage was assessed using a modified version of the 
comet assay, as described by Azqueta et  al.12 The number of FPG-
sensitive sites was obtained by the difference between the % Tail DNA 
in the buffer-incubated slide and that in the FPG-incubated slide.
2.4. Slides scoring
Blind sample scoring of 100 cells [50 cells per duplicate gel] was car-
ried out using a fluorescence microscope under ×40 objective obser-
vation [Eclipse E400, Nikon Instruments, Japan]. The Comet Assay 
IV [Perceptive Instruments, UK] software was used for DNA meas-
urements, and the parameter used to measure DNA damage was % 
Tail DNA [Figure 1], here referred as ‘arbitrary unit’ [AU], and rec-
ommended for being the most reliable comet assay measurement.10,13
2.5. Lipid peroxidation
Lipid peroxidation was determined by the thiobarbituric acid reac-
tive substances [TBARS] protocol for malondialdehyde [MDA] 
quantification, following the protocol described by Ohkawa et al.14 
(a) (b) (c) (d)
Figure 1. DNA damage measured by comet assay in lymphocytes. [a] Sample from healthy control [S4 – male, 26 years – 3.4% Tail DNA]; [b] Sample from 
ulcerative colitis [UC] patient [S120 – male, 41 years, 5-ASA – 2.8% Tail DNA]; [c] Sample from Crohn’s disease [CD] patient [S136 – female, 35 years, anti-tumour 
necrosis factor alpha [anti-TNFα] – 9.0% Tail DNA]; [d] Sample from UC patient [S178 – female, 28 years, azathioprine + anti-TNFα – 15.9% Tail DNA] [arrows 
indicating the tail DNA].
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with slight modifications. A  calibration curve was prepared with 
MDA as a standard, and the results were expressed in micromolar 
MDA. All samples gave results that were within the linear range of 
the MDA standard curve.
2.6. Plasma protein carbonyls [PPCs]
Detection of carbonyl groups in plasma was performed using the 
Protein Carbonyl Content Assay Kit [Sigma-Aldrich™, USA] and the 
Bicinchoninic Acid Kit for Protein Determination [Sigma-Aldrich™, 
USA], following the manufacturer’s instructions. The results 
obtained were expressed in nanomole carbonyls per milligram of 
plasma protein.
2.7. Total antioxidant capacity
The total antioxidant capacity [TAC] of plasma was determined 
using the assay kit ‘Antioxidant Assay Kit’ [Cayman™, USA] accord-
ing to manufacturers’ instructions, and measuring both aqueous- 
and lipid-soluble antioxidants. The results obtained were expressed 
in terms of millimolar of Trolox equivalent per litre.
2.8. Statistics
The study population size was calculated with the ‘Open Source 
Epidemiologic Statistics for Public Health – OpenEPI’, available 
at www.OpenEpi.com, based on the ‘Frequency in a Population’ 
tool. For the size of the Portuguese IBD population, estimated at 
15 460 patients, studying 344 subjects gave the study greater than 
a 90% confidence level and, based on the difference in the mean 
values for DNA damage between cases and controls previously 
established, a statistical power of 100% by the normal approxi-
mation method.
Categorical variables were described as absolute frequencies [n] 
and relative frequencies [%]. Descriptive statistics (median and inter-
quartile range [IQR], and percentages for continuous and categori-
cal variables, respectively) were calculated for all variables. Missing 
data were excluded from analyses; on average, <2% of data were 
missing. When testing a hypothesis about continuous variables, non-
parametric tests [Mann–Whitney or Kruskall–Wallis] were used, 
as appropriate, taking into account normality assumptions and 
the number of groups compared. When testing a hypothesis about 
categorical variables, a chi-square test and Fisher’s exact test were 
used, as appropriate. All the reported p values were two-sided, and p 
values < 0.05 were considered statistically significant. All data were 
arranged, processed and analysed with SPSS© v. 20.0 data [Statistical 
Package for Social Sciences, IBM]. The predictors for DNA dam-
age and oxidative DNA damage were assessed by univariate and 
multivariate analysis linear regression, and 95% confidence intervals 
were considered to make inferences with the regression coefficients; 
the tested independent variables were age, sex, C-reactive protein 
[C-RP], therapy, disease location, disease behaviour [for CD], age at 
diagnosis, years of follow-up, number of flares per year of follow-up, 
and smoking habits.
3. Results
3.1. Baseline characteristics
Relevant demographic and clinical characteristics of the enrolled 
subjects are described in Table 1. In total, 344 cases and 294 controls 
were included. Although a sex- and age-matched control population 
was recruited, it significantly differed from the IBD population in 
age distribution [p = 0.0151]. Also, CD and UC patients significantly 
Table 1. Demographic and clinical characteristics of enrolled subjects {median (interquartile range [IQR] 25–75)}.
  Controls IBD CD UC p1 p2 p3
[n = 294] [n = 344] [n = 221] [n = 123]
Sex [% men/% women] 55.1/44.9 50.4/49.6 55.5/44.5 41.5/58.5 0.982* 0.011*† 0.015*†
Age (median [IQR 25–75]) 43 [33–50] 39 [30–49] 36 [27–47] 43 [35–55] <0.001† 0.169 <0.001†
Smoking [% yes/% no] NA 20.1/79.9 26.1/73.9 7.8/92.2 – – <0.001*†
C-RP [mg/mL] (median [IQR 25–75]) – 2.1 [0.9–6.6] 2.60 [1.1–7.90] 1.8 [0.8–4.0] – – 0.022†
C-RP <3 mg/mL n [%] – – 92 [46%] 70 [63%] – – –
C-RP ≥3mg/mL n [%] – – 109 [54%] 42 [37%] – – –
Disease location [%]: – – – –
CD [L1/L2/L3] 46.4/13.6/40.0 – – – –
UC [E1/E2/E3] – – 33.6/27.1/39.3 – – –
Behaviour [%] [B1/B2/B3] – – 47.7/22.0/30.3 – – – –
Therapeutics % –
5-ASA – – 15.9 42.6 – – –
Azathioprine – – 37.0 33.9 – – –
Anti-TNFα – – 24.5 12.2 – – –
Azathioprine + anti-TNFα – – 22.6 11.3 – – –
Years of follow-up (median [IQR 25–75]) – – 8 [4–12] 9 [5–13] – – 0.534
Number of flares/years of disease  
(median [IQR 25–75])
– – 0.2 [0.1–0.3] 0.16 [0.08–0.27] – – 0.551
Time on 5-ASA [months] (median  
[IQR 25–75])
– – 139.6 [52.8–217.5] 80.9 [35.4–143.2] – – 0.055
Time on azathioprine [months]  
(median [IQR 25–75])
– – 40.4 [13.3–82.1] 43.6 [19.4–98.8] – – 0.518
Time on anti-TNFα [months]  
(median [IQR 25–75])
– – 38.6 [17.0–67.5] 40.4 [13.3–58.6] – – 0.599
Time on azathioprine + anti-TNFα  
[months] (median [IQR 25–75])
– – 46.2 [24.0–70.8] 17.7 [10.1–43.6] – – 0.100
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differed in gender distribution [p = 0.015], median age [p < 0.001], 
and smoking habits [p  < 0.001]. Univariate analysis was made to 
account for confounders, age, and sex, and significant differences 
[p < 0.001] were found for DNA damage in CD (β-value [95% CI]: 
5.3 [4.4–6.1]) and UC (β-value [95% CI]: 3.2 [0.2–4.2]) in reference 
to the control group, and for oxidative DNA damage in CD (β-value 
[95% CI]: 1.4 [0.6–2.1]) and UC (β-value [95% CI]: 2.6 [1.7–3.6]) 
in reference to the control group. Disease activity was measured by 
C-RP levels [cut-off: >3 mg/mL] and number of flares per year of 
follow-up. The two groups of patients significantly differed for C-RP 
[p = 0.022], with CD exhibiting a higher level and also a larger frac-
tion of subjects with C-RP above the cut-off; no significant differ-
ences were found for number of flares per year or years of follow-up 
[Table 1].
3.2. Oxidative damage markers among IBD 
population
Oxidative damage markers were measured in all subjects. The IBD 
population exhibited a statistically significant increase in DNA 
damage [9.0 AU; IQR: 5.4–13.4] [p < 0.001] and a statistically sig-
nificant increase in oxidative DNA damage [4.0 AU; IQR: 2.1–7.5] 
[p < 0.001], when compared with controls [Figures 2 and 3]. The 
differences observed for lipid peroxidation and protein carbonyla-
tion were not statistically significant, but the TAC was significantly 
higher in IBD patients than in controls [p < 0.001] [Supplementary 
material – Table 1].
CD patients exhibited a statistically significant increase in DNA 
damage [9.7 AU; IQR: 6.2–14.0] when compared with the UC popu-
lation [7.1 AU; IQR: 4.6–11.7] [p < 0.001], but significantly lower 
oxidative DNA damage [3.6 AU; IQR: 1.8–3.8 vs. 4.6 AU; IQR: 2.4–
8.1] [p = 0.048] [Figures 2 and 3]. No significant differences were 
found between CD and UC patients for lipid peroxidation, protein 
carbonylation, or TAC [Supplementary material – Table 1].
Each group of patients was subgrouped according to age [grouped 
as <20, 21–30, 31–40, 41–50, >50 years] [Supplementary material – 
Tables 2 and 3], smoking habits [smokers, former smokers, and 
never smokers] [Supplementary material – Table 4], and therapeutic 
[5-ASA, azathioprine, anti-TNFα, and combined therapy] [Tables 2 
and 3] to look for significant differences.
3.3. CD population
3.3.1. Age
Between the defined age groups, DNA damage was significantly dif-
ferent [p = 0.002]; the highest level was found in patients between 
21 and 30 years old and the lowest in patients under 20 years of age 
[Supplementary material – Table  2]. Under linear regression anal-
ysis, DNA damage showed a significant negative correlation with 
age [rs = –0.179, p = 0.009]. Number of flares per year of follow-
up was found to be significantly different for different age groups 
[p < 0.001], with the group under 20 years exhibiting the highest 
level and the group over 50 years the lowest [Supplementary mate-
rial – Table 2].
3.3.2. Disease activity and disease phenotype
Between the C-RP  <  3 mg/mL and C-RP≥3 mg/mL groups, DNA 
damage [9.5 AU; IQR: 6.1–13.9, and 10.7 AU; IQR: 6.8–14.5, 
respectively; p  =  0.4] and oxidative DNA damage [4.4 AU; IQR: 
2.3–8.5, and 4.2 AU; IQR: 2.2–6.9, respectively; p = 0.520] were 
not statistically different. C-RP levels were not statistically different 
between age groups, smoking habits, or therapeutic. DNA damage 
was not found to be significantly different for ‘number of flares per 
year of follow-up’ distribution [Supplementary material – Figure 3]. 
Disease behaviour subgrouping did not reveal a significant differ-
ence for DNA damage [B1: 11.1 AU, IQR: 6.3–16.9; B2: 9.6 AU, 
IQR: 6.8–13.5; B3: 8.9 AU, IQR: 5.9–12.1, p  =  0.056], nor did 
location [L1: 9.1 AU, IQR: 5.9–13.9; L2: 9.4 AU, IQR: 6.6–13.4; 
L3: 10.5, IQR: 6.7–14.9, p = 0.459]. Oxidative DNA damage dif-
ference was also found to be non-significant for disease behaviour 
subgrouping [B1: 4.2 AU, IQR: 2.1–6.8; B2: 3.3 AU, IQR: 1.4–5.8; 
B3: 3.1 AU, IQR: 1.7–5.6, p = 0.512] and disease location [L1: 4.0 
AU, IQR: 1.5–7.4; L2: 3.1 AU, IQR: 1.7–6.9; L3: 3.2, IQR: 2.1–5.0, 
p = 0.840]. Total antioxidant status was significantly different for 
40
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Figure  2. DNA damage measured in controls (5.4 arbitrary units [AU]; 
interquartile range [IQR]: 3.8–6.8), irritable bowel disease [IBD] population 
[9.0 AU; IQR: 5.4–13.4], Crohn’s disease [CD] [9.7 AU; IQR: 6.2–14.0] and 
ulcerative colitis [UC] patients [7.1 AU; IQR: 4.6–11.7] [box-plot: medians, IQRs 
25–75, max–min] [Mann–Whitney U test; ***p < 0.001].
***
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Figure  3. Oxidative DNA damage [median] measured in controls (2.3 
arbitrary units [AU]; interquartile range [IQR]: 1.2–4.2), irritable bowel disease 
[IBD] population [4.0 AU; IQR: 2.1–7.5], CD [3.6 AU; IQR: 1.8–3.8] and UC 
patients [4.6 AU; IQR: 2.4–8.1] [box-plot: medians, IQRs 25–75, max–min] 
[Mann–Whitney U test; *p < 0.05; ***p < 0.001].
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disease behaviour, with B1 exhibiting the lowest level [1.0 mM; IQR: 
0.8–1.2] and B3 the highest [1.1 mM; IQR: 1.0–1.3] [p = 0.022].
3.3.3. Smoking habits
The measured oxidative DNA damage in smokers was significantly 
higher when compared with former-smokers [p = 0.006] and never-
smokers [p = 0.018]. No significant differences were found for DNA 
damage, lipid peroxidation, protein carbonyls or total antioxidant 
status [Supplementary material – Table 4].
3.3.4. Therapeutic subgroups
For CD patients, DNA damage was significantly different between thera-
peutic groups [p = 0.010], with azathioprine exhibiting the lowest value, 
and the combined therapy [azathioprine + anti-TNFα] the highest [Table 2] 
[Supplementary material – Figure 1]. Significant differences were also found 
for lipid peroxidation [p = 0.002] and total antioxidant status [p < 0.001]. 
Regarding oxidative DNA damage, no statistically significant differences 
were observed between groups [Table 2]. CD patients on 5-ASA exhibited 
the highest levels of lipid peroxidation and total antioxidant status. The 
azathioprine group showed the lowest values for lipid peroxidation. In the 
anti-TNFα group, we found the lowest total antioxidant capacity [Table 2]. 
Number of flares per year of follow-up was significantly different between 
the therapeutic groups [p = 0.004], being highest in the combined therapy 
group and lowest in the 5-ASA group [Table 2] [Figure 4].
3.4. Univariate and multivariate analysis
Univariate analysis of DNA damage predictors [Supplementary 
material – Table 5] found a significant negative correlation with age 
Table 2. Results for oxidative damage markers {DNA damage, oxidative DNA damage, lipid peroxidation (thiobarbituric acid reactive sub-
stances [TBARS], protein carbonylation [PCC])}, total antioxidant capacity [TAC], C-reactive protein [C-RP], and number of flares/year of 
follow-up for CD population stratified for therapy – 5-ASA, azathioprine, anti-TNFα, and combined therapy of azathioprine and anti-TNFα 
[AU: arbitrary units] {median (interquartile range [IQR] 25–75)}.
Crohn’s disease
N = 208
  5-ASA Azathioprine Anti-TNFα Azathioprine + anti-TNFα p
[n = 33] [n = 77] [n = 51] [n = 47]
DNA damage [AU] (median [IQR 25–75]) 10.5 [4.8–14.9] 8.7 [6.2–11.8] 10.1 [6.1–18.5] 11.6 [9.5–14.3] 0.010†a
Oxidative DNA damage [AU] (median [IQR 25–75]) 4.4 [1.4–5.9] 4.0 [2.0–6.8] 3.6 [2.0–8.9] 3.2 [1.6–4.3] 0.613
TBARS [ųM] (median [IQR 25–75]) 4.8 [4.2–5.4] 4.1 [3.3–5.0] 4.2 [3.6–5.3] 4.6 [4.0–5.7] 0.002†b
PCC [nmol/mg prot] (median [IQR 25–75]) 0.9 [0.8–0.9] 0.8 [0.8–0.9] 0.8 [0.7–0.9] 0.8 [0.7–0.9] 0.445
TAC [mM] (median [IQR 25–75]) 1.2 [0.9–1.3] 1.1 [1.0–1.3] 0.9 [0.8–1.1] 1.0 [0.8–1.3] <0.001†c
C-RP [mg/L] (median [IQR 25–75]) 1.3 [0.4–6.0] 1.9 [1.1–7.2] 4.5 [1.3–10.5] 3.1 [1.3–5.5] 0.063
No. flares/years of follow-up (median [IQR 25–75]) 0.1 [0.0–0.2] 0.1 [0.1–0.1] 0.2 [0.1–0.3] 0.2 [0.1–0.3] 0.004†d
p-values refer to Kruskall–Wallis test. †Statistically significant [P < 0.05];
p-values for multiple comparisons with Bonferroni post hoc:
†a – Azathioprine vs. azathioprine + anti-TNFα [p < 0.001];
†b – 5-ASA vs. azathioprine [p = 0.048]; azathioprine vs. azathioprine + anti-TNFα [p < 0.001];
†c – 5-ASA vs. anti-TNFα [p = 0.018]; azathioprine vs. Anti-TNFα [p < 0.001];
†d – 5-ASA vs. azathioprine [p = 0.012]; 5-ASA vs. anti-TNFα [p = 0.03]; 5-ASA vs azathioprine + anti-TNFα [p < 0.006].
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Figure 4. Distribution of DNA damage [median + SEM] and Disease Activity [No. of flares/year of follow-up] for Crohn’s disease [CD] and ulcerative colitis [UC] 
patients.
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and significant association with disease behaviours B1 [inflamma-
tory] and B2 [structuring] [p < 0.001 and p = 0.003, respectively]. 
Under univariate analysis of oxidative DNA damage [Supplementary 
material – Table 6], we found positive significant correlation for A3 
[over 40 years old] group of ‘age at diagnosis’ [p = 0.015], for smok-
ers, and for sex. On multivariate analysis [Supplementary material 
– Table  5], no significant associations were found for DNA dam-
age; however, for oxidative DNA damage [Supplementary material 
– Table 6], a significant association was found with the A3 group of 
‘age at diagnosis’ [over 40 years old] [p = 0.025], and sex.
3.5. UC population
3.5.1. Age
Between the defined age groups, no significant differences were 
observed for the studied oxidative damage markers [Supplementary 
material – Table 3]. Under linear regression analysis, DNA damage 
and lipid peroxidation showed a significant negative correlation with 
age [rs = –0.211, p = 0.020 and rs = –0.190, p = 0.039, respectively]. 
Number of flares per year of follow up was found to be significantly 
different for the various age groups distribution [p = 0.005], with 
the 21–30 years age group exhibiting the highest level and the group 
over 50 years old exhibiting the lowest [Supplementary material – 
Table 3].
3.5.2. Disease activity and disease phenotype
Between the C-RP < 3 mg/mL and C-RP ≥ 3 mg/mL groups, DNA 
damage [7.7 AU; IQR: 4.6–11.8, and 7.7 AU; IQR: 4.2–11.0, 
respectively; p  =  0.707] and oxidative DNA damage [4.4 AU; 
IQR: 2.5–8.3, and 5.3 AU; IQR: 2.6–9.3, respectively; p = 0.512] 
were not statistically different. C-RP levels were not statisti-
cally different between age groups, smoking habits, or thera-
peutic group. DNA damage was found significantly different for 
‘number of flares per year of follow-up’ distribution [p = 0.012] 
[Supplementary material – Figure 4] and for disease location with 
E1 exhibiting the lowest level [4.2 AU; IQR: 3.3–5.0] and E2 the 
highest [8.3 AU; IQR: 4.7–12.4] [E3: 8.0 AU; IQR: 4.6–12.1] 
[p = 0.005].
3.5.3. Smoking habits
We found no significant differences for any of the oxidative damage 
markers or TAC between these groups. It is noteworthy that in the 
UC group, the number of smokers is quite small [7.8%], thus pos-
sibly misleading [Supplementary material – Table 4].
3.5.4. Therapeutic subgroups
In UC patients, DNA damage was found to be significantly different 
[p < 0.001] between the various therapeutic options [Supplementary 
material – Figure  2] [Table  3]; the lowest value was obtained for 
the 5-ASA group and the highest for the combined therapy [aza-
thioprine + anti-TNFα]. Differences in oxidative DNA damage, lipid 
peroxidation, protein carbonylation, and TAC were non-significant 
[Table 3]. The number of flares per year of follow-up was found to 
be significantly different between the therapeutic groups [p < 0.001], 
being highest for the combined therapy group and lowest for the 
5-ASA group [Table 3] [Figure 4].
3.6. Univariate and multivariate analysis
Associations with DNA damage were found under univariate analy-
sis for age, therapeutic groups, disease locations [E2 and E3], ‘age 
at diagnosis’ [A3 group], and disease activity measured by number 
of flares per year of follow-up [Supplementary material – Table 7]. 
Under univariate analysis, association with oxidative DNA damage 
was found for smokers, yet due to the small number of included 
subjects [n  =  9], these results should be considered cautiously 
[Supplementary material – Table 8].
Multivariate analysis for factors associated with DNA damage 
[Supplementary material – Table  7] found significant β-values for 
therapeutic groups and for ‘sex’. No significant associations were 
found for oxidative DNA damage under multivariate analysis 
[Supplementary material – Table 8].
4. Discussion
To our best knowledge, this is the largest study performed over a rep-
resentative IBD population assessing both peripheral and oxidative 
DNA damage and involving a stratified approach to analysing the 
Table 3. Results for oxidative damage markers {DNA damage, oxidative DNA damage, lipid peroxidation (thiobarbituric acid reactive sub-
stances [TBARS]), Protein carbonylation [PCC]}, total antioxidant caspacity [TAC], C-reactive protein [C-RP], and number of flares/year of 
follow-up for UC population stratified for therapy – 5-ASA, azathioprine, anti-TNFα, and combined therapy of azathioprine and anti-TNFα 
[AU: arbitrary units] {median (interquartile range [IQR] 25–75)}.
Ulcerative colitis
N = 115
  5-ASA Azathioprine Anti-TNFα Azathioprine + anti-TNFα p
N = 49 N = 39 N = 14 N = 13
DNA damage [AU] (median [IQR 25–75]) 4.7 [3.6–7.1] 10.4 [7.6–13.6] 7.5 [3.1–17.0] 12.4 [10.6–15.0] <0.001†a
Oxidative DNA damage [AU] (median [IQR 25–75]) 4.4 [2.2–9.1] 5.9 [2.3–8.1] 4.2 [1.3–8.5] 4.4 [2.5–6.6] 0.945
TBARS [ųM] (median [IQR 25–75]) 4.6 [3.6–5.4] 4.6 [3.4–5.2] 5.4 [5.1–6.3] 4.5 [3.8–5.1] 0.05
PCC [nmol/mg prot] (median [IQR 25–75]) 0.8 [0.8–0.9] 0.8 [0.7–1.0] 0.9 [0.7–1.0] 0.8 [0.7–1.0] 0.957
TAC [mM] (median [IQR 25–75]) 1.0 [0.9–1.2] 1.1 [0.9–1.3] 1.0 [0.9–1.1] 1.0 [0.8–1.3] 0.553
C-RP [mg/L] (median [IQR 25–75]) 2.2 [0.8–4.0] 1.9 [0.8–3.9] 1.8 [0.7–8.0] 1.1 [0.4–2.1] 0.244
No. flares/years of follow-up (median [IQR 25–75]) 0.1 [0.0–0.2] 0.1 [0.1–0.4] 0.2 [0.1–0.3] 0.3 [0.2–0.5] <0.001†b
p-values refer to Kruskall–Wallis test. †Statistically significant [p < 0.05]; 
p-values for multiple comparisons with Bonferroni post hoc:
†a – 5-ASA vs. azathioprine [p < 0.001]; 5-ASA vs. azathioprine + anti-TNFα [p < 0.001];
†b – 5-ASA vs. azathioprine [p < 0.001]; 5-ASA vs. azathioprine + anti-TNFα [p = 0.006].
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results. Our findings confirmed that IBD was related to higher levels of 
peripheral and oxidative DNA damage, when compared with a healthy 
population. These increases differed between CD and UC patients. 
Peripheral DNA damage was significantly higher in CD than in UC, 
yet oxidative DNA damage was significantly higher in UC patients. The 
observed differences between CD and UC may indicate that the sys-
temic involvement of CD results in higher steady-state levels of DNA 
damage. Moreover, the higher oxidative DNA damage observed in 
UC patients might indicate some downregulation of DNA repair sys-
tems, as studies have shown that defects in the ability to repair 8-oxo-
7,8-dihydro-2'-deoxyguanosine [8-oxo-dG] result in the accumulation 
of endogenously produced oxidized DNA bases, and increased sus-
ceptibility to tumour development.15,16 Oxidative DNA damage levels 
in IBD patients has already been reported in small studies measuring 
8-hydroxy-2'-deoxyguanosine [8-OHdG]  either in CD or UC patients’ 
colon biopsies or plasma, all of them observing higher levels in patients 
compared with controls and/or higher levels in inflamed tissues com-
pared with non-inflamed tissues.17–21 Risques et al.22 found significantly 
higher levels of DNA damage in the colonocytes of UC patients between 
30 and 59 years when compared with controls, but failed to relate this 
increase to duration, age of disease onset, disease activity, or medication. 
Unlike other studies,20,23–29 in our work no significant differences for 
lipid or protein oxidation products between patients and controls were 
observed. However, some inconsistency is found in the literature as oth-
ers30,31 also report no significant differences for lipid peroxidation levels.
Regarding ‘age at diagnosis’, univariate analysis showed it to be 
an individual risk for oxidative DNA damage in CD patients and for 
DNA damage in UC patients, but with contrasting effects—for CD 
A3 [over 40 years] is the risk group, whereas in UC A3 is protective 
against DNA damage. Some cancers have been associated with young 
age of disease onset for IBD, e.g. cervical dysplasia and non-Hodg-
kin lymphoma.32 Nevertheless, Fries et al.33 report that IBD patients 
diagnosed over the age of 40 years more frequently develop tumours 
[p < 0.000], and Baars et al.,34 in a large retrospective study with 251 
IBD patients with diagnosed IBD-related colorectal cancer [CRC], 
found older age at onset of IBD to be a risk factor for developing CRC. 
Taken all together, these facts indicate that age at diagnosis might be 
a useful predictor for oxidative DNA damage burden through disease 
course, and as seen before, through DNA repair failure. Our results 
also revealed that in CD, disease behavior B1 [inflammatory] and B2 
[structuring], and in UC, disease locations E2 and E3, and disease bur-
den, namely number of flares/year of follow-up, constitute risk factors 
for DNA damage, indicating that inflammation is a major contribu-
tor to DNA damage in IBD patients. Although a clear definition for 
aggressive UC has not yet been determined, it is known that in UC 
the severity of the disease is proportional to the amount of inflamed 
colon involved, and some studies show that E2 and E3 phenotypes are 
associated with more complicated disease.35 Moreover, regarding IBD, 
the extent of inflammatory lesions, the duration of the disease, and the 
presence of active chronic inflammation have all been pointed out as 
risk factors for CRC.36 Furthermore, we found significant differences 
in peripheral DNA damage between the therapeutic groups, both in 
CD and UC. The combined therapy with azathioprine and anti-TNFα 
exerted the highest levels of peripheral DNA damage, both in CD and 
UC. The lowest DNA damage levels were found for the azathioprine 
group in CD patients and for the 5-ASA group in UC patients. UC 
patients on 5-ASA, besides having the lowest number of flares per year 
of follow-up [i.e. less active disease], exhibited the lowest level of DNA 
damage; the value found was even lower than the DNA damage found 
in controls, and this could be attributed to the antioxidant and free 
radicals scavenging action of 5-ASA. Concerns for therapeutic-related 
carcinogenicity have reported in the literature. Azathioprine, anti-TNF, 
and the combination of both drugs have been associated with increased 
risk of lymphomas.37 In IBD patients, high risk for non-melanoma skin 
cancer38 and lymphomas39,40 have been related to exposure to azathio-
prine. In addition to lymphomas, anti-TNF has been associated with 
increased risk for melanoma37; combined therapy of azathioprine and 
anti-TNFα has been associated with a specifically increased risk for 
hepatosplenic T-cell lymphoma.41 Our results showed that CD patients 
had an increased level of DNA damage when undergoing anti-TNFα 
therapy, compared with azathioprine, and the highest DNA damage 
level for the combined therapy, both in CD and UC; despite this, oxida-
tive DNA damage levels did not differ between all groups.
5. Conclusion
The strengths of this study lie in the well-established cohort, the pro-
spective nature of the study, and the fact that it is one of the larg-
est studies performed measuring oxidative damage markers in IBD 
patients. Nevertheless, the small number of UC patients in some of 
the subgroups, namely smokers and patients under 16 years of age, 
constitutes a weakness that could only be circumvented by including 
patients from other referral centres. In view of our results, we con-
cluded that DNA damage was evident among IBD patients, and that 
age at diagnosis, inflammatory burden, and therapeutic options might 
be associated with DNA damage levels. The predictors found for DNA 
damage and oxidative DNA damage might be useful in the assess-
ment of individual susceptibilities to IBD-related cancers. Moreover, 
the oxidative DNA damage levels in UC patients may indicate some 
impairment of the DNA repair systems in these patients, and this 
should be thoroughly assessed in future research. Although estab-
lishing the occurrence of oxidative damage is an important step in 
determining the pathophysiology of the disease, it does not determine 
whether oxidative stress is a cause or a consequence of the disease. 
Yet as a first step, it might open ways to explore these pathways and 
promote research studies targeting the benefits of and the potential 
for developing pharmacological antioxidant agents, as well as alerting 
physicians to potential implications concerning the disease phenotype.
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